Houston, April 9, 2025 - Velvet therapeutics, an early-stage biotech company focusing on developing novel chimeric antigen receptor using a non-viral, DNA delivery platform will be presenting at the American Society of Gene and Cell Therapy in New Orleans from March 13-18, 2025. The presentation will debut in vitro efficacy of Velvet's first proprietary solid tumor CAR. Details of the presentation are as follows:  
Title: In Vivo CAR Delivery as Supercoiled DNA with Lymphatic Tropism Polyasparagine Nanoparticles
Date: May 13, 2025
Time: 6:00 PM - 7:30 PM
Room: Poster Hall Hall I2